The way the glucagon receptor works is key to the safety profile of retatrutide
(30) The mechanism underlying these increased risks remains unclear, though they may be related to semaglutides effects on cardiovascular function, fluid balance, and insulin-glucagon dynamics
Ultimately, payers need to balance the costs and benefits of these drugs for their members
(In fact, 36% of people with overweight or obesity actually went back on GLP-1s after quitting because they regained weight.) It happens a lot in practice, says Simonetti
Patients considering compounded therapies should speak directly with a licensed healthcare provider to understand regulatory and safety differences
However, it is very important for healthcare professionals at York University and McMaster University to monitor use to lower risks